| 1 |
26734075 | Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study. | 2016 |
4 |
| 2 |
25560470 | Pharmacogenomics of glinides. | 2015 Jan |
2 |
| 3 |
26417414 | Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study. | 2015 Sep |
2 |
| 4 |
26548081 | Interaction of mouse intestinal P-glycoprotein with oral antidiabetic drugs and its inhibitors. | 2015 Sep |
1 |
| 5 |
24461109 | Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. | 2014 Mar |
1 |
| 6 |
22982177 | Evaluating insulin secretagogues in a humanized mouse model with functional human islets. | 2013 Jan |
1 |
| 7 |
23631607 | Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes. | 2013 Jun |
1 |
| 8 |
22727067 | Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. | 2012 Jul |
4 |
| 9 |
21185798 | Diabetes prevention: can insulin secretagogues do the job? | 2011 Jul |
2 |
| 10 |
21548456 | Hypersensitivity to repaglinide. | 2011 |
1 |
| 11 |
21801074 | Quo vadis nateglinide? Ten-year perspective. | 2011 Sep |
2 |
| 12 |
20334663 | Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. | 2010 Mar 24 |
1 |
| 13 |
20865534 | Modeling of ATP-sensitive inward rectifier potassium channel 11 and inhibition mechanism of the natural ligand, ellagic acid, using molecular docking. | 2010 |
2 |
| 14 |
19755410 | Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. | 2009 Dec |
1 |
| 15 |
30780794 | Combination of nateglinide with thiazolidinediones in Type 2 diabetes. | 2009 Nov |
2 |
| 16 |
18792871 | Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function? | 2008 Sep |
1 |
| 17 |
17298589 | Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. | 2007 Apr |
3 |
| 18 |
17316868 | Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. | 2007 Sep |
1 |
| 19 |
17376293 | Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. | 2007 Apr |
2 |
| 20 |
17425753 | Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. | 2007 Mar-Apr |
2 |
| 21 |
17587398 | Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. | 2007 Jul |
4 |
| 22 |
16214255 | Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. | 2006 Mar |
6 |
| 23 |
16443858 | Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. | 2006 Feb |
5 |
| 24 |
16842480 | Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. | 2006 Jul |
1 |
| 25 |
17003289 | Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. | 2006 Sep |
2 |
| 26 |
17050498 | Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes. | 2006 Jul-Aug |
1 |
| 27 |
15715891 | Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days. | 2005 Mar |
5 |
| 28 |
15724236 | No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. | 2005 Jul-Aug |
1 |
| 29 |
15871845 | Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis. | 2005 Feb |
1 |
| 30 |
15986773 | Indication for nateglinide in type 2 diabetes mellitus. | 2005 Jun 1 |
2 |
| 31 |
16178991 | Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. | 2005 Oct |
2 |
| 32 |
16260353 | Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals. | 2005 Nov-Dec |
5 |
| 33 |
14709397 | Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways. | 2004 Jan |
1 |
| 34 |
14746575 | A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes. | 2004 Mar |
3 |
| 35 |
14748619 | Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. | 2004 |
1 |
| 36 |
15005635 | Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. | 2004 |
1 |
| 37 |
15133755 | The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. | 2004 May-Jun |
1 |
| 38 |
15155541 | Acute and long-term effects of nateglinide on insulin secretory pathways. | 2004 May |
2 |
| 39 |
15317602 | A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. | 2004 Sep |
1 |
| 40 |
15375790 | Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus. | 2004 Oct |
1 |
| 41 |
12652357 | The mechanisms underlying the unique pharmacodynamics of nateglinide. | 2003 Mar |
3 |
| 42 |
12766094 | Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. | 2003 Jun |
1 |
| 43 |
12860494 | The effect of nateglinide taken with food on gastric emptying rates in healthy subjects. | 2003 Jun |
1 |
| 44 |
12877088 | [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]. | 2003 Jul |
1 |
| 45 |
12940610 | Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. | 2003 Aug |
1 |
| 46 |
12965106 | Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes. | 2003 Sep |
7 |
| 47 |
14581145 | Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model. | 2003 Nov |
6 |
| 48 |
15058753 | Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide. | 2003 Nov-Dec |
2 |
| 49 |
11782867 | Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. | 2002 Jan |
2 |
| 50 |
11902096 | Restoring post-prandial insulin release in type 2 diabetes. | 2002 Feb |
1 |